Physician profile
Elsy V Navas
NPI 1447493275
$233,657.46
in general payments reported to CMS, 2019-2025
32 companies · $164K in 2025
The $164K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,477 · 2020: $1,797 · 2021: $3,379 · 2022: $2,446 · 2023: $4,064 · 2024: $56K · 2025: $164K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Honoraria: $44K · Consulting Fee: $32K · Travel and Lodging: $20K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,283.89 |
| Honoraria | $43,820.00 |
| Consulting Fee | $31,950.00 |
| Travel and Lodging | $20,388.62 |
| Food and Beverage | $12,115.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $68,376.11 | 2022-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $32,722.16 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $28,103.08 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24,201.49 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $20,493.83 | 2024-2025 | |
| Bridgebio Pharma, INC. | $15,093.14 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals Lp | $12,524.42 | 2023-2025 | Wainua, Farxiga |
| Lilly USA, LLC | $12,220.00 | 2024-2025 | Jardiance |
| Abiomed | $5,028.61 | 2019-2025 | Impella |
| Abbott Laboratories | $3,736.89 | 2019-2025 | Navitor |
| Edwards Lifesciences Corporation | $3,496.64 | 2020-2025 | Pascal |
| Medtronic, INC. | $1,104.17 | 2021-2025 | Azure Xt Dr Mri Surescan, Micra, Aurora Ev-Icd Mri Surescan |
| Cardiva Medical, INC. | $1,103.77 | 2019-2023 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Boston Scientific Corporation | $851.86 | 2019-2024 | Watchman Flx |
| Cvrx, INC. | $820.42 | 2019-2025 | Barostim Neo System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $656.56 | 2019-2025 | |
| Vital Connect, INC | $630.04 | 2023 | Vitalpatch Rtm |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $610.07 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $294.64 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $226.21 | 2023-2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $219.43 | 2023-2024 | Optimizer, Optimizer |
| Astellas Pharma US INC | $202.18 | 2020-2025 | |
| Cordis US Corp. | $200.18 | 2025 | Mynx Control Venous |
| Medtronic Vascular, INC. | $182.29 | 2019 | |
| Zoll Circulation INC | $168.50 | 2025 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Livanova USA, INC. | $136.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.53 | 2025 | |
| Merck Sharp & Dohme LLC | $50.72 | 2025 | Verquvo |
| Amgen INC. | $46.44 | 2024-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $28.58 | 2025 | Uptravi |
| United Therapeutics Corporation | $20.24 | 2019 | |
| Esperion Therapeutics, INC. | $19.82 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsy Navas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.